Redesigned protein accelerates blood clotting
Study holds hope for next generation hemophilia treatment Researchers have doubled the potency of a protein that drives blood to clot, according to research to be published in the July 26 edition of Biochemistry. The study results may have profound implications for the treatment of hemophilia, the inherited blood disorder that causes easy or excessive bleeding in 30,000 Americans. In...Georgia Tech accelerates drug discovery with new IBM supercomputing cluster
The Center will use IBM technologies to advance research into new drugs for the treatment of some of today's most life-threatening diseases, including cancer. The Center's research will be headed by one of the world's leading systems biologists, Dr. Jeffrey Skolnick, the Georgia Research Alliance Eminent Scholar in Computational Systems Biology. Funded by $8.5 million in grants from the St...One-dimensional diffusion accelerates molecular motors
Max Planck scientists have identified a new strategy which motor proteins use to move. The research was carried out by Prof. Jonathon Howard and Stefan Diez at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden. The motor protein MCAK (Mitotic Centromere Associated Kinesin) goes into action at the end of microtubules where it disassembles them. This is in contrast...Gene therapy accelerates healing of damaged skeletal muscle
A new retrospective study in the Canadian Medical Association Journal shows that young farm children, particularly boys, are about twice as likely as the total population of young Canadian children to die from an injury. Brison and colleagues collected and analyzed Canadian data on fatal agricultural injuries to young children to determine rates, identify patterns and devise prevention str...Fiserv accelerates clearing of checks
, a division of the Brookfield-based information management firm Fiserv, announced on Thursday that it has completed enhancement of its ExchangeGuard suite of applications. The augmentations are geared specifically toward improving the se...EpiCept Accelerates Development of Phase I Clinical Study for Cancer
EpiCept Corporation today announced that with the initiation of a new study center, Tower Cancer Research Foundation in Los Angeles, it will accelerate the recruitment of patients in the currently ongoing Phase I clinical study of EPC2407, a novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. T...